John H Fetting

Associate Professor

1973 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where John H Fetting is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Pathogenic Germline Variants in Patients with Metastatic Breast Cancer

Stuttgen, K., Croessmann, S., Fetting, J. H., Stearns, V., Nunes, R., Connolly, R. M. & Park, B. H., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalLetter

Sharing in care: engaging care partners in the care and communication of breast cancer patients

Wolff, J. L., Aufill, J., Echavarria, D., Heughan, J. A. A., Lee, K. T., Connolly, R. M., Fetting, J. H., Jelovac, D., Papathakis, K., Riley, C., Stearns, V., Thorner, E., Zafman, N., Levy, H. P., Dy, S. M. & Wolff, A. C., Jan 1 2019, In : Breast Cancer Research and Treatment.

Research output: Contribution to journalArticle

  • A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

    Santa-Maria, C., Bardia, A., Blackford, A. L., Snyder, C., Connolly, R., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., Quinlan, K., Rosner, G., Slater, S., Storniolo, A. M., Wolff, A. C., Zorzi, J., Henry, N. L. & Stearns, V., May 11 2018, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-9 9 p.

    Research output: Contribution to journalArticle

  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer

    Litvak, A., Batukbhai, B., Russell, S. D., Tsai, H. L., Rosner, G., Jeter, S. C., Armstrong, D. K., Emens, L. A., Fetting, J. H., Wolff, A. C., Silhy, R., Stearns, V. & Connolly, R., Jan 1 2018, (Accepted/In press) In : Cancer.

    Research output: Contribution to journalArticle

  • Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: A phase II national cancer institute/stand up to cancer study

    Connolly, R., Li, H., Jankowitz, R. C., Zhang, Z., Rudek-Renaut, M., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., Brufsky, A., Piekarz, R., Ahuja, N., Laird, P. W., Shen, H., Weisenberger, D. J., Cope, L., Herman, J. G., Somlo, G., Garcia, A. A. & 5 others, Jones, P. A., Baylin, S. B., Davidson, N. E., Zahnow, C. & Stearns, V., Jun 1 2017, In : Clinical Cancer Research. 23, 11, p. 2691-2701 11 p.

    Research output: Contribution to journalArticle